Metabolomic and Lipidomic Analysis of the Colorectal Adenocarcinoma Cell Line HT29 in Hypoxia and Reoxygenation.
colorectal adenocarcinoma
hypoxia
lipidomics
metabolomics
reoxygenation
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
23 Jul 2023
23 Jul 2023
Historique:
received:
22
06
2023
revised:
19
07
2023
accepted:
20
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The poor availability of oxygen and nutrients in malignant tumors drives the activation of various molecular responses and metabolic reprogramming in cancer cells. Hypoxic tumor regions often exhibit resistance to chemotherapy and radiotherapy. One approach to enhance cancer therapy is to indirectly increase tumor oxygen availability through targeted metabolic reprogramming. Thus, understanding the underlying metabolic changes occurring during hypoxia and reoxygenation is crucial for improving therapy efficacy. In this study, we utilized the HT29 colorectal adenocarcinoma cell line as a hypoxia-reoxygenation model to investigate central carbon and lipid metabolism. Through quantitative NMR spectroscopy and flow injection analysis - differential mobility spectroscopy-tandem mass spectrometry (FIA-DMS-MS/MS) analysis, we observed alterations in components of mitochondrial metabolism, redox status, specific lipid classes, and structural characteristics of lipids during hypoxia and up to 24 h of reoxygenation. These findings contribute to our understanding of the metabolic changes occurring during reoxygenation and provide the basis for functional studies aimed at metabolic pathways in cancer cells.
Identifiants
pubmed: 37512582
pii: metabo13070875
doi: 10.3390/metabo13070875
pmc: PMC10384744
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Colciencias
ID : 756/2016
Références
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Br J Radiol. 2020 Nov 1;93(1115):20200067
pubmed: 32462882
J Lipid Res. 2008 May;49(5):1137-46
pubmed: 18281723
Nature. 2011 Nov 20;481(7381):380-4
pubmed: 22101433
Br J Radiol. 2019 Jan;92(1093):20170843
pubmed: 29436847
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Metabolites. 2022 Oct 27;12(11):
pubmed: 36355113
Cell Metab. 2006 Mar;3(3):187-97
pubmed: 16517406
Anal Chem. 2021 Dec 14;93(49):16369-16378
pubmed: 34859676
Anal Bioanal Chem. 2020 Apr;412(10):2353-2363
pubmed: 32055910
Cancer Chemother Pharmacol. 1992;30(4):277-80
pubmed: 1643695
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19611-6
pubmed: 22106302
Drug Metab Dispos. 2020 May;48(5):378-385
pubmed: 32156684
J Clin Invest. 2013 Sep;123(9):3685-92
pubmed: 23999443
Signal Transduct Target Ther. 2020 Oct 7;5(1):227
pubmed: 33028824
J Physiol Pharmacol. 1998 Jun;49(2):303-10
pubmed: 9670113
Cell Rep. 2018 Sep 4;24(10):2596-2605.e5
pubmed: 30184495
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Nat Cell Biol. 2022 Feb;24(2):230-241
pubmed: 35145222
Br J Cancer. 2005 Dec 12;93(12):1356-63
pubmed: 16333244
Nat Metab. 2022 Jun;4(6):711-723
pubmed: 35739397
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Nat Rev Cancer. 2008 Jun;8(6):425-37
pubmed: 18500244
Cell Rep. 2014 Oct 9;9(1):349-365
pubmed: 25263561
Cell Metab. 2019 Apr 2;29(4):856-870.e7
pubmed: 30686744
Science. 2004 Apr 23;304(5670):554
pubmed: 15016963
Clin Cancer Res. 2013 Dec 15;19(24):6741-50
pubmed: 24141625
Nat Commun. 2016 Jun 20;7:11971
pubmed: 27321283
Anal Chim Acta. 2017 Aug 8;980:1-24
pubmed: 28622799
Int J Mol Sci. 2019 Nov 30;20(23):
pubmed: 31801289
EMBO Rep. 2012 Mar 01;13(3):251-7
pubmed: 22310300
Trends Cell Biol. 2014 Aug;24(8):472-8
pubmed: 24985940
Sci Adv. 2021 Oct 08;7(41):eabi7511
pubmed: 34613776
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
Nat Commun. 2019 Feb 22;10(1):903
pubmed: 30796225
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Front Cell Dev Biol. 2021 Apr 15;9:631163
pubmed: 33937232
J Am Soc Mass Spectrom. 2021 Nov 3;32(11):2655-2663
pubmed: 34637296
Cell Metab. 2006 Mar;3(3):177-85
pubmed: 16517405
J Exp Clin Cancer Res. 2021 Jun 21;40(1):197
pubmed: 34154610
Nat Rev Cancer. 2016 Sep 23;16(10):663-73
pubmed: 27658636
J Biol Chem. 2011 Apr 15;286(15):13041-51
pubmed: 21335549
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3434-E3443
pubmed: 28396387